Ranibizumab in neovascular age-related macular degeneration

By K. Eng, P. Kertes. Clinical Interventions in Aging, 2006

2,830 citations recorded by the source corpus.

Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.

Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/f76379eb3228a933d252eb46b3bd6038d06ee3d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

  1. Tien Yin Wong
  2. David M. Brown
  3. SriniVas R. Sadda
  4. D. Boyer
  5. N. Ferrara
  6. A. Adamis

In Radiology, Nuclear Medicine and Imaging

  1. Tien Yin Wong
  2. SriniVas R. Sadda
  3. D. Boyer
  4. David M. Brown

Citations in the corpus